埃克替尼与重组人血管内皮抑素持续泵入联用治疗EGFR突变阳性非小细胞肺癌的临床研究

目的:探讨埃克替尼与重组人血管内皮抑素持续泵入联用治疗EGFR突变阳性非小细胞肺癌的临床疗效。方法:将晚期EGFR突变阳性非小细胞肺癌患者40例随机分为试验组与对照组两组,每组20例。对照组接受单药埃克替尼250 mg/tid治疗;试验组接受埃克替尼联合重组人血管内皮抑素(恩度):埃克替尼250 mg/tid+重组人血管内皮抑素30 mg d1～7,持续泵入治疗。21 d为一个周期,直到疾病进展或出现不可接受毒性。比较两组患者近期疗效、无进展生存期、总生存期、客观缓解率(ORR)、毒副反应和生活质量。结果:试验组患者完全缓解率明显高于对照组,差异有统计学意义(P <0. 05);试验组总缓解率明显高于对照组,差异有统计学意义(P <0. 05);两组患者治疗后生活质量明显高于治疗前,且试验组患者生活质量优于对照组,差异有统计学意义(P <0. 05)。结论:埃克替尼联合重组人血管内皮抑素持续泵入治疗EGFR突变阳性非小细胞肺癌临床疗效显著,毒副反应较少,能有效的提高肿瘤病人的生活质量。埃克替尼与重组人血管内皮抑素持续泵入联用治疗EGFR突变阳性非小细胞肺癌具有借鉴性。

Clinical research on treatment of EGFR mutation-positive non-small cell lung cancer with combination between icotinib hydrochloride and recombinant human endostatin continuously pumped

Objective:Research and discuss the clinical effect of combination between icotinib hydrochloride and recombinant human endostatin continuously pumped on treatment of EGFR mutation-positive non-small cell lung cancer.Methods:Divide 40 cases of patients suffering from EGFR mutation-positive non-small cell lung cancer into two groups，including the experimental group and control group，each of which has 20 cases.Patients take single drug of icotinib hydrochloride（250 mg/tid) in control group or combination between icotinib hydrochloride and endostar（250 mg/tid of icotinib hydrochloride+30 mg d1~7 of recombinant human endostatin continuously pumped) in experimental group.21 days a cycle until the progression of disease or unacceptable toxicity exists.To compared the short-term effect，progression free survival，overall survival，objective remission rate（ORR)，toxic and side effect and living quality between the two groups.Results:The complete remission rate of experimental group is obviously higher than that of control group，and the distinct difference exists（P<0.05).The overall remission rate of experimental group is obviously higher than that of control group，and the difference has the statistical significance（P<0.05).The living quality of two groups of patients after the treatment is apparently higher than that before the treatment，and the living quality of patients in experimental group is superior to that in control group.Therefore，the difference has the statistical significance（P<0.05).Conclusion:The clinical effect of combination between icotinib hydrochloride and recombinant human endostatin continuously pumped on treatment of EGFR mutation-positive NSCLC is remarkable.The combination of two drugs has fewer adverse reactions and can effectively improve the quality of life of the tumor patients.The treatment of EGFR mutation-positive non-small cell lung cancer with combination between icotinib hydrochloride and recombinant human endostatin continuously pumped has reference value.